-
Podcast: Introducing Insight Unpacked, Season 3
Introducing Insight Unpacked Season 3: Can We Still Build a Green Economy? Insight in your inbox Receive our newsletters to keep up with the latest research and ideas from faculty at the Kellogg School of Management. https://insight.kellogg.northwestern.edu/newsletter/insightful-leader In the last decade, we’ve seen powerful people and organizations take on the issue of climate change—making big… →
-
Building Resilience, One Lap at a Time
Long before his business and teaching career, Carter Cast received an early lesson in what excellence demands. Before taking on leadership roles at Walmart.com, PepsiCo, and Blue Nile, Cast first chased excellence in a different lane: swimming. In his youth, the clinical professor of strategy at the Kellogg School was an extraordinarily talented swimmer. He… →
-
Bright IDEAS-YA Skills Training and Psychosocial Outcomes of Young Adults With Cancer: A Randomized Clinical Trial
CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of Bright IDEAS-YA, intervention participants had significantly reduced distress and improved HRQOL relative to control. These findings suggest that Bright IDEAS-YA may be offered as supportive care for YAs with cancer to improve psychosocial outcomes. →
-
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial
CONCLUSION: Based on this simulation model, using head-to-head SURMOUNT-5 trial data, tirzepatide (MTD) had lower total costs and higher QALYs compared to semaglutide (MTD). This supports that tirzepatide (MTD) is a cost-effective treatment option for individuals with obesity or overweight compared to semaglutide (MTD). →
-
Sirolimus plus roxadustat synergistically enhances immunosuppression and erythropoiesis in pure red cell aplasia: a multicenter trial
Acquired pure red cell aplasia (aPRCA) is rare and challenging to treat. We investigated the efficacy and safety of sirolimus plus roxadustat in patients with aPRCA (Chinese Clinical Trial Register number, ChiCTR2200065107). We enrolled 82 patients with aPRCA in this prospective single-arm, open-label, multicenter trial between October 2022 and January 2024. Treatment response and safety… →
-
Developing Hospital at Home tariffs in Denmark: a time-driven activity-based microcosting approach within a randomised controlled trial
CONCLUSIONS: A transparent and reproducible tariff-development framework for HaH services was established using TDABC and microcosting. The model aligns reimbursement with actual resource use and care complexity and provides a transferable template for economic evaluation and operational planning. →
-
How AI Helps the Best and Hurts the Rest
Mark Shaver/theispot.com Can generative AI serve as an effective adviser for business owners and entrepreneurs? Intuitive chat-based natural language interfaces mean that anyone who can read and write can use GenAI tools for a wide range of tasks, even if they lack technical skills. This has obvious appeal for entrepreneurs and small business owners, many… →
-
Comparison of Compound Lidocaine Cream and Lidocaine-Prilocaine Cream for Pain Management in Facial Rejuvenation: A Randomized Controlled Trial
CONCLUSION: Compound lidocaine cream demonstrated superior analgesic efficacy in this clinical comparison; however, differences in anesthetic concentration, application technique, and lack of participant blinding should be considered when interpreting these findings. Larger studies with standardized dosing and blinding are warranted. →
-
Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome
Plozasiran (Redemplo), a novel small interfering RNA (siRNA) therapeutic targeting the hepatic biosynthesis of apolipoprotein C-III (APOC3), is approved by the US FDA for treating familial chylomicronemia syndrome (FCS), a disease of rare prevalence that presents with extremely elevated levels of serum triglycerides (TG) leading to a higher risk of acute pancreatitis. Plozasiran is also… →
-
Back squat and deadlift fatiguing protocols elicit distinct countermovement jump profiles: phase-specific predictors and soreness responses
INTRODUCTION OR BACKGROUND: Residual fatigue following resistance exercise can impair neuromuscular performance. The back squat (BSQ) and deadlift (DL) are key lower-limb exercises but may differ in their fatigue and recovery profiles. Identifying phase-specific markers during the countermovement jump (CMJ) may improve monitoring and guide recovery strategies. →
